Raymond James & Associates’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-30,175
| Closed | -$882K | – | 4056 |
|
|
2024
Q1 | $882K | Buy |
30,175
+11,160
| +59% | +$343K | ﹤0.01% | 2670 |
|
|
2023
Q4 | $642K | Sell |
19,015
-3,344
| -15% | -$97.8K | ﹤0.01% | 2802 |
|
|
2023
Q3 | $686K | Sell |
22,359
-16,948
| -43% | -$611K | ﹤0.01% | 2689 |
|
|
2023
Q2 | $1.58M | Sell |
39,307
-512
| -1% | -$21.2K | ﹤0.01% | 2202 |
|
|
2023
Q1 | $1.63M | Sell |
39,819
-39
| -0.1% | -$1.55K | ﹤0.01% | 2170 |
|
|
2022
Q4 | $1.54M | Buy |
39,858
+4,261
| +12% | +$207K | ﹤0.01% | 2168 |
|
|
2022
Q3 | $1.89M | Sell |
35,597
-3,489
| -9% | -$194K | ﹤0.01% | 1998 |
|
|
2022
Q2 | $2.28M | Buy |
39,086
+3,787
| +11% | +$248K | ﹤0.01% | 1913 |
|
|
2022
Q1 | $2.69M | Buy |
35,299
+791
| +2% | +$52.7K | ﹤0.01% | 1925 |
|
|
2021
Q4 | $2.08M | Buy |
34,508
+3,800
| +12% | +$210K | ﹤0.01% | 2149 |
|
|
2021
Q3 | $1.72M | Buy |
30,708
+1,929
| +7% | +$111K | ﹤0.01% | 2209 |
|
|
2021
Q2 | $1.75M | Sell |
28,779
-424
| -1% | -$26.8K | ﹤0.01% | 2190 |
|
|
2021
Q1 | $2.05M | Buy |
29,203
+24,365
| +504% | +$1.74M | ﹤0.01% | 1996 |
|
|
2020
Q4 | $290K | Sell |
4,838
-2,444
| -34% | -$143K | ﹤0.01% | 3143 |
|
|
2020
Q3 | $438K | Buy |
7,282
+2,496
| +52% | +$145K | ﹤0.01% | 2727 |
|
|
2020
Q2 | $251K | Sell |
4,786
-2,569
| -35% | -$107K | ﹤0.01% | 3016 |
|
|
2020
Q1 | $247K | Sell |
7,355
-1,458
| -17% | -$60.6K | ﹤0.01% | 2897 |
|
|
2019
Q4 | $399K | Buy |
8,813
+2,000
| +29% | +$84.9K | ﹤0.01% | 2896 |
|
|
2019
Q3 | $259K | Sell |
6,813
-1,375
| -17% | -$54.9K | ﹤0.01% | 3100 |
|
|
2019
Q2 | $356K | Sell |
8,188
-11,675
| -59% | -$496K | ﹤0.01% | 2904 |
|
|
2019
Q1 | $756K | Sell |
19,863
-3,298
| -14% | -$129K | ﹤0.01% | 2369 |
|
|
2018
Q4 | $996K | Buy |
+23,161
| New | +$1.08M | ﹤0.01% | 2090 |
|
|
2018
Q3 | – | Sell |
-21,611
| Closed | -$693K | – | 3696 |
|
|
2018
Q2 | $693K | Buy |
21,611
+3,850
| +22% | +$133K | ﹤0.01% | 2454 |
|
|
2018
Q1 | $553K | Sell |
17,761
-50,930
| -74% | -$1.81M | ﹤0.01% | 2501 |
|
|
2017
Q4 | $3.14M | Buy |
68,691
+2,216
| +3% | +$87.8K | 0.01% | 1400 |
|
|
2017
Q3 | $2.5M | Buy |
66,475
+41,630
| +168% | +$1.68M | 0.01% | 1495 |
|
|
2017
Q2 | $1.19M | Buy |
24,845
+14,307
| +136% | +$664K | ﹤0.01% | 1915 |
|
|
2017
Q1 | $481K | Buy |
10,538
+3,910
| +59% | +$169K | ﹤0.01% | 2404 |
|
|
2016
Q4 | $214K | Sell |
6,628
-9,279
| -58% | -$310K | ﹤0.01% | 2848 |
|
|
2016
Q3 | $544K | Buy |
15,907
+1,882
| +13% | +$73.7K | ﹤0.01% | 2221 |
|
|
2016
Q2 | $473K | Buy |
14,025
+1,935
| +16% | +$95.1K | ﹤0.01% | 2131 |
|
|
2016
Q1 | $641K | Buy |
+12,090
| New | +$707K | ﹤0.01% | 1922 |
|
|
2015
Q3 | – | Sell |
-58,755
| Closed | -$4.16M | – | 2351 |
|
|
2015
Q2 | $4.16M | Sell |
58,755
-35,982
| -38% | -$2.83M | 0.02% | 904 |
|
|
2015
Q1 | $8.42M | Buy |
94,737
+5,755
| +6% | +$584K | 0.04% | 516 |
|
|
2014
Q4 | $7.89M | Sell |
88,982
-3,205
| -3% | -$303K | 0.04% | 491 |
|
|
2014
Q3 | $8.94M | Sell |
92,187
-9,980
| -10% | -$971K | 0.05% | 397 |
|
|
2014
Q2 | $9.38M | Sell |
102,167
-11,410
| -10% | -$869K | 0.06% | 376 |
|
|
2014
Q1 | $7.95M | Buy |
113,577
+11,477
| +11% | +$781K | 0.05% | 397 |
|
|
2013
Q4 | $5.87M | Buy |
102,100
+30,600
| +43% | +$1.61M | 0.04% | 470 |
|
|
2013
Q3 | $3.44M | Sell |
71,500
-26,000
| -27% | -$947K | 0.03% | 626 |
|
|
2013
Q2 | $2.83M | Buy |
+97,500
| New | +$2.82M | 0.03% | 652 |
|
Other funds holding PCRX
FCM
SIMG
